



**L<sup>2</sup> Diagnostics, LLC**  
**PO Box 8175**  
**New Haven, CT 06530-0175**

20 March, 2007


To: Edward Hammond  
The Sunshine Project  
1920 Stuart St.  
Berkeley, CA 94703

Dear Sir:

Pursuant to the request by The Sunshine Project under the Public Access Provisions of the NIH guidelines requesting copies of L2 Diagnostics, LLC Institutional Biosafety Committee minutes, enclosed are all the meeting minutes from May 1, 2003 to present:

1. Institutional Biosafety Committee Minutes from June 28, 2005.
2. Institutional Biosafety Committee minutes from December 12, 2006.

Respectfully,

  
Jonathan Alderman  
Chairman, L2 Diagnostics  
Biosafety Committee



**L<sup>2</sup> Diagnostics, LLC**  
**PO Box 8175**  
**New Haven, CT 06530-0175**

**Minutes of Biosafety committee meeting held June 28, 2005, 5:00-6:00pm**

**Attendees:**

Ruth Montgomery  
Jon Alderman  
Barbara Kazmierczak  
Cara Case  
Mark Blazejak  
Michel Ledizet  
Kali Kar  
Ray Koski  
Karen Anthony  
Member(s) absent: Michael Cappello  
Guest(s): Nathalie Bonafe

**New Business:**

RK: brief West Nile virus project descriptions in layman terms  
ML: brief Antithrombotic and Immunosuppressant project descriptions in layman terms

Brief self-introduction of attendees

JA: Power Point presentation- role of IBC

**General question:**

MB: Would all work be done here?  
RK: Half done at L2 and half at Yale or Connecticut Agricultural Experiment Station (CAES)

**Protocol Review:**

ML leaves the room

*1. Therapeutic activity of a novel tick immunosuppressant*

JA: Any questions, concerns, the protocol is open for discussion?  
BK: Is Salp15 purified protein toxic to mucus membranes  
RK: No known toxicity associated with the protein, plus it is an immunosuppressant  
Project approved

*2. Preclinical development of the tsetse thrombin inhibitor*

JA: Any questions, concerns, the protocol is open for discussion?  
All: None  
JA: Motion to approve and seconded.  
JA: Protocol approved.

Project approved

RK leaves the room

*3. Recombinant subunit WNV vaccine development, Vaccination against WNV, Small molecule inhibitors of WNV infection, Protection against WNV by RNA interference.*

JA: Any questions, concerns, the protocol is open for discussion?

BK: Small molecule inhibitors of WNV infection: Are virus-like particles infectious and how much viral genome used to construct particles?

KA: Virus-like particles are non-infectious. Less than 2/3 of WNV genome is used.

RM: If need to add new bacterial, insect or mammalian cell lines in protocols, does the committee have to meet again?

JA: Not necessary for committee to reconvene. But L2 needs e-mail or written approval from committee to add or modify any protocols.

JA: Any other concerns?

All: None

JA: Motion to approve and seconded.

JA: Protocols approved.

*4. Eastern Equine Encephalitis (EEE) Vaccine and Immunotherapy*

JA: Any questions, concerns, the protocol is open for discussion?

BK: Is EEE really a risk group 2?

ML and KA: Yes, it is classified as such in BMBL manual

BK: How much virus genome is used and where and how the genome will be manipulated?

ML: Less than 2/3 genome is used. Viral genome will be isolated at CAES and pcr will be performed there. Only gel purified pcr fragment will be brought to L2.

JA: Any other concerns?

All: No

JA: Motion to approve and seconded.

JA: Protocol approved.

*5. Antibody prophylaxis and therapy of flavivirus infection*

JA: Any questions, concerns, the protocol is open for discussion?

BK: Infectious dengue genome a concern?

KA: L2 has dengue genomic RNA; however it would not be propagated in mammalian cell lines to generate infectious particles. The genomic RNA will be used only as a template to pcr amplify the genes of interest.

JA: Any other concerns?

All: No

JA: Motion to approve and seconded.

JA: Protocol approved

Approximately 6:00 pm meeting adjourned.



**L<sup>2</sup> Diagnostics, LLC**  
**PO Box 8175**  
**New Haven, CT 06530-0175**

**Minutes of Biosafety committee meeting held Dec 12, 2006, 5:15-6:15pm**

**Attendees:**

Ruth Montgomery  
Jon Alderman (Chairperson)  
Barbara Kazmierczak  
Mark Blazejak  
Michel Ledizet  
Nathalie Bonafe  
Kalipada Kar  
Raymond Koski  
Karen Anthony  
Member(s) absent: Cara Case  
Guests: Martin Mattessich  
Paul Kaplan  
Ada Vaill

**Brief self-introduction of attendees**

JA: L2 was certified as BSL II by CT state in August 18, 2006

KA: Described process of BSL II certification

KA: L2 filed annual report with NIH Office of Biotechnology Activities. Next report due by May 18, 2007

**Protocol Review:**

*1. Glioma therapeutics targeting glioma pathogenesis-related protein*

NB: Brief project introduction

NB leaves the room

JA: Any questions, concerns, the protocol is open for discussion?

JA: Need biosafety approval for immunizing rabbits to raise antisera

KA: Rabbit immunization done by contractor- Cocalico Biologicals

JA: Include Cocalico Biologicals assurance number with protocol

BK: error on P4 section 2b – work does **not** involve DNA from human or animal **pathogens**

RK: BSL requirement of cell lines used?

KA: All cell lines obtained from ATCC designated as BSL I

BK: Enclose product information sheet for each cell line with protocol

RK: Protocol should be classified as 'exempt' since no DNA from human or animal pathogens used

NB: Incorporates suggested changes into protocol  
Project approved by committee

BK: Are there any new employees added to existing protocols? If so, the protocols should be updated. How are new employees trained?

KA: Existing protocols haven't yet been updated to include new employees but this will be implemented immediately. New employees are required to complete an online biosafety course, and the training record is documented.

JA: 'Sunshine Project' introduction- request to release minutes of biosafety committee meetings to Sunshine Project committee.

JA will review NIH policy and Freedom of Information Regulations and will determine when and how to release the minutes.

New protocol:

Glioma therapeutic targeting glioma pathogenesis-related protein.

Active protocols:

Recombinant subunit West Nile virus vaccine development  
Vaccination against West Nile virus  
Small molecule inhibitors of West Nile infection  
Antibody prophylaxis and therapy of flavivirus infection  
Protection against West Nile virus by RNA interference

No longer active protocols:

Therapeutic activity of a novel tick immunosuppressant  
Preclinical development of the tsetse thrombin inhibitor  
Eastern Equine Encephalitis vaccine and immunotherapy

6:15 pm meeting adjourned.